{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:50:17Z","timestamp":1761663017487,"version":"3.44.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jinf.2011.10.016","type":"journal-article","created":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T05:20:24Z","timestamp":1322716824000},"page":"204-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatic safety of efavirenz in HIV\/hepatitis C virus-coinfected patients with advanced liver fibrosis"],"prefix":"10.1016","volume":"64","author":[{"given":"Juan A.","family":"Pineda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Neukam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Cart\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"de Los Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Jim\u00e9nez-Exp\u00f3sito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","series-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","key":"10.1016\/j.jinf.2011.10.016_bib1"},{"key":"10.1016\/j.jinf.2011.10.016_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008","volume":"9","author":"BG Gazzard on behalf of the BHIVA Treatment Guidelines Writing Group","year":"2008","journal-title":"HIV Medicine"},{"key":"10.1016\/j.jinf.2011.10.016_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV Infection. 2008 Recommendations of the International AIDS Society \u2013 USA Panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2011.10.016_bib4","unstructured":"Clumeck N, Dedes N, Pozniak A, Raffi F, The ECAS Executive Committee. Clinical management and treatment of HIV-infected adults in Europe. Available from: http:\/\/www.europeanaidsclinicalsociety.org\/guidelinespdf\/1_Treatment_of_HIV_Infected_Adults.pdf [accessed 2 June 2010]."},{"key":"10.1016\/j.jinf.2011.10.016_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.antiviral.2009.10.021","article-title":"Viral hepatitis and HIV-coinfection","volume":"85","author":"Soriano","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.jinf.2011.10.016_bib6","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2893.2009.01229.x","article-title":"Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV\/hepatitis C virus-coinfected patients","volume":"17","author":"Pineda","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jinf.2011.10.016_bib7","unstructured":"Bristol-Myers S. Sustiva\u00ae (efavirenz): full prescribing information. Available from: http:\/\/packageinserts.bms.com\/pi\/pi_sustiva.pdf [accessed 2 June 2010]."},{"key":"10.1016\/j.jinf.2011.10.016_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/jac\/dkn531","article-title":"Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C","volume":"63","author":"Meynard","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2011.10.016_bib9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/512086","article-title":"Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C","volume":"195","author":"Barreiro","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2011.10.016_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2011.10.016_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2011.10.016_bib12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jac\/dkn045","article-title":"Liver toxicity of antiretroviral combinations including atazanavir\/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis","volume":"61","author":"Pineda","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2011.10.016_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dkn429","article-title":"Hepatic safety of tipranavir plus ritonavir (TPV\/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis","volume":"63","author":"Mac\u00edas","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2011.10.016_bib14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/521857","article-title":"The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C coinfection","volume":"45","author":"Vergara","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2011.10.016_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/135965350901400214","article-title":"Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation","volume":"14","author":"Vispo","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2011.10.016_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2011.10.016_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cgh.2008.11.019","article-title":"Accuracy of simple biochmical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus","volume":"7","author":"Tural","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jinf.2011.10.016_bib18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1086\/605676","article-title":"Natural history of compensated hepatitis C virus-related cirrhosis in human immunodeficiency virus-infected patients","volume":"49","author":"Pineda","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2011.10.016_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.aids.0000198087.47454.e1","article-title":"Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease","volume":"20","author":"Merchante","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2011.10.016_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-na\u00efve patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2011.10.016_bib21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":"Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-na\u00efve HIV-infected adults","volume":"39","author":"DeJesus","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2011.10.016_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2011.10.016_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine","volume":"4","author":"Martin-Carbonero","year":"2003","journal-title":"HIV Clin Trials"},{"issue":"2","key":"10.1016\/j.jinf.2011.10.016_bib24","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1086\/381453","article-title":"Liver injury during highly active antiretroviral therapy: the effects of hepatitis C coinfection","volume":"38","author":"Bonacini","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2011.10.016_bib25","doi-asserted-by":"crossref","first-page":"e11416","DOI":"10.1371\/journal.pone.0011416","article-title":"Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection","volume":"5","author":"Grant","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jinf.2011.10.016_bib26","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00126334-200309011-00005","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients","volume":"34","author":"Stern","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2011.10.016_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors","volume":"59","author":"Rivero","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2011.10.016_bib28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2011.10.016_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/135965350901400116","article-title":"Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study","volume":"14","author":"van Luin","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2011.10.016_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/509580","article-title":"The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients","volume":"44","author":"McGovern","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2011.10.016_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","article-title":"The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml","volume":"24","author":"Arribas","year":"2010","journal-title":"AIDS"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445311005603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445311005603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:16:14Z","timestamp":1759007774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445311005603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0163445311005603"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2011.10.016","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic safety of efavirenz in HIV\/hepatitis C virus-coinfected patients with advanced liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2011.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}